|Articles|September 18, 2019

UV Disinfection Tackles MRSA—What About C Diff?

Can UV disinfecting lights tackle health care-associated infections?

Health care environments are dirty. There’s no way of avoiding it — hospitals, urgent care facilities, and other medical centers are constantly battling microorganisms. Cleaning and disinfection are critical in these environments to help reduce the risk of transmission. Consider that roughly 1 in 100 people carry methicillin-resistant Staphylococcus aureus (MRSA) while 1 in 3 carry drug-susceptible S aureus in their nose.

Organisms like MRSA, Candida auris, and Clostridioides difficile, are known to cause diseases in these settings and are often culprits in health care-associated infections. Effectively removing these organisms from the environment is critical for infection control efforts. While disinfecting wipes and sprays have been the go-to for decades, ultraviolet-A (UV-A) light exposure has been growing in popularity. While UV-A is a method for disinfecting surfaces and objects, it can’t sterilize products, but it can help reduce bio-burden in patient rooms, waiting areas, operating rooms, and other high-risk areas. Like many new technologies, UV-A disinfection is still finding its way into hospitals as people become more comfortable with its infection control capabilities.

A new study tested the efficacy of UV-A disinfection for decontamination against health care-associated pathogens on surfaces. The researchers used a ceiling light fixture for the UV-A source, testing its efficacy on killing microorganisms by assessing recovery on a version of the American Society for Testing Materials standard quantitative carrier disk test method. This disk includes a strain of MRSA, C diff, C auris, and 2 kinds of virus bacteriophages. The efficacy of the UV-A light was also evaluated for its capabilities of reducing contamination of 32 in-use portable pieces medical equipment. Doppler ultrasound machines, glucometers, wheelchairs, and workstations-on-wheels were some of the equipment tested by being placed 2 meters from the light source for 4 hours.

Researchers found that these 4 hours yielded a significant reduction in pathogenic microorganisms from the medical equipment in use and mostly on the disks. There was a modest reduction in MRSA, C auris, and the bacteriophages, but not C diff spores. “C diff spores were not reduced or minimally reduced after 24 hours of exposure to UV-A at 3 W/m2 (0-0.2 log10 CFU reduction),” the authors wrote.

Prior to the use of the UV-A disinfection of the medical equipment, 37% yielded pathogenic microorganisms, while only 10% did after the disinfection, which was statistically significant.

The authors note that these findings suggest the potential for UV-A disinfection to aid in the reduction of pathogenic microorganisms that contribute to health care-associated infections. There should be a concern though for the health and safety of those exposed, which amplifies the importance of manufacturer guidance and proper protocols. Moreover, this component might increase the required cleaning time for certain areas, which should be considered prior to use.

While the UV-A disinfecting light did provide a modest reduction in microorganisms, the resilience of C diff and the existing microbial burden should not be forgotten. UV-A light has shown promise in its capabilities to reduce microorganisms in health care environments; however, it cannot and should not be a substitute for the manual cleaning and disinfection that is required to remove biofilm and other hardier bioburden.


Related to this article

LMN-201 Reduces C difficile Recurrence
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.